Kanzius Noninvasive Radiowave Cancer Treatment Positioned to Go to the FDA - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Kanzius Noninvasive Radiowave Cancer Treatment Positioned to Go to the FDA As FDA Process Proceeds, Kanzius Cancer Research Foundation Realizes Ultimate Goal


Kanzius Noninvasive Radiowave Cancer Treatment Positioned to Go to the FDA

As FDA Process Proceeds, Kanzius Cancer Research Foundation Realizes Ultimate Goal

PR Newswire

ERIE, Pa., May 20, 2014 /PRNewswire/ -- Before losing his bout with leukemia in 2009, John Kanzius vowed to find "a better way" to treat cancer. Today, more than four decades after the US declared "war on cancer," we are one step closer to a world where cancer is treated with no side effects.

In the coming weeks, a research team led by Drs. Steven Curley, Stuart Corr, and Rita Serda will submit an application to the Food & Drug Administration (FDA), to initiate human clinical trials for the Kanzius Noninvasive Radiowave Treatment, under the auspices of AkesoGenX, owners of the technology patents.

Final testing is currently being conducted at the request of FDA consultants and the research team is confident these tests will yield positive results.  With an FDA application in sight, the Kanzius Foundation has now reached the peak of its progress and has funded all of the necessary research to go to human trials, and as a result will close its doors on June 30, 2014.

"Since 2008, supporters of the Kanzius project have donated more than $15 million," said Mark Neidig Sr., executive director of Kanzius Cancer Research Foundation. "These donations have come from all over the world and show the cancer community's commitment to finding a better way. This is a day that we have all been working so hard for and waiting for with such great anticipation. This is a day of celebration for the cancer community."

Remaining true to its mission and the cancer community it serves, after closing on June 30th, the Kanzius Foundation will grant all of its remaining assets and donations to three newly created funds at the Regional Cancer Centers in Erie and Fort Myers and at Houston's Baylor College of Medicine. Each fund, bearing John Kanzius' name, will provide resources for the institutions to conduct human clinical trials. These funds will also provide a new platform for supporters to continue to contribute philanthropically in the years to come. 

About the Kanzius Cancer Research Foundation

Kanzius Cancer Research Foundation is a 501(c)(3) non‐profit organization with a mission to create national and global awareness of the potentials of the Kanzius Noninvasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses through human trials. The goal of the Kanzius Foundation is to raise money to support ongoing research grants. Pancreatic, liver and colorectal cancers in test subjects are undergoing extensive research in Houston and Pittsburgh; additional, ongoing studies are currently focused on breast, leukemic, lung, melanomic, osteocarcenomic and prostate cancers. For more information about the Kanzius research, visit www.Kanzius.org.

 

SOURCE Kanzius Cancer Research Foundation

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here